These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27526062)

  • 1. Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.
    Nishikawa M; Miyake H; Gleave M; Fujisawa M
    Target Oncol; 2017 Feb; 12(1):69-79. PubMed ID: 27526062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
    Kususda Y; Miyake H; Gleave ME; Fujisawa M
    Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin.
    Zellweger T; Miyake H; July LV; Akbari M; Kiyama S; Gleave ME
    Neoplasia; 2001; 3(4):360-7. PubMed ID: 11571636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
    Mahalingam D; Medina EC; Esquivel JA; Espitia CM; Smith S; Oberheu K; Swords R; Kelly KR; Mita MM; Mita AC; Carew JS; Giles FJ; Nawrocki ST
    Clin Cancer Res; 2010 Jan; 16(1):141-53. PubMed ID: 20028765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
    Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
    Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
    Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin promotes growth and invasion of clear cell renal carcinoma cell by upregulation of S100A4 expression.
    Liu Y; Men C; Xu Y; Zhao K; Luo L; Dong D; Yu Q
    Cancer Biomark; 2018; 21(4):915-923. PubMed ID: 29400663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.
    So A; Sinnemann S; Huntsman D; Fazli L; Gleave M
    Mol Cancer Ther; 2005 Dec; 4(12):1837-49. PubMed ID: 16373699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
    Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
    Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
    Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
    Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
    Muramaki M; So A; Hayashi N; Sowery R; Miyake H; Fujisawa M; Gleave ME
    BJU Int; 2009 Feb; 103(3):384-90. PubMed ID: 19007378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.
    Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E
    Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
    Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temsirolimus, the mTOR inhibitor, induces autophagy in adenoid cystic carcinoma: in vitro and in vivo.
    Liu W; Huang S; Chen Z; Wang H; Wu H; Zhang D
    Pathol Res Pract; 2014 Nov; 210(11):764-9. PubMed ID: 24767255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
    Tang Y; Liu F; Zheng C; Sun S; Jiang Y
    J Exp Clin Cancer Res; 2012 Sep; 31(1):73. PubMed ID: 22967941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
    Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
    Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
    Cao C; Shinohara ET; Li H; Niermann KJ; Kim KW; Sekhar KR; Gleave M; Freeman M; Lu B
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1228-36. PubMed ID: 16253777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and genomic characterization of patient-derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma.
    Sakamoto H; Yamasaki T; Sumiyoshi T; Takeda M; Shibasaki N; Utsunomiya N; Arakaki R; Akamatsu S; Kobayashi T; Inoue T; Kamba T; Nakamura E; Ogawa O
    Cancer Med; 2021 Jan; 10(1):119-134. PubMed ID: 33107222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.